605527151	605527151	CD	B-NP	O
|	|	NN	I-NP	O
AMH	AMH	NN	I-NP	O
|	|	NN	I-NP	O
91358655	91358655	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
2766747	2766747	CD	B-NP	O
|	|	CC	I-NP	O
7/16/2006	7/16/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
FEVER	FEVER	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Unsigned	Unsigned	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
5/10/2006	5/10/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Unsigned	Unsigned	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
5/10/2006	5/10/2006	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
BAIRAM	BAIRAM	NN	B-NP	O
,	,	,	O	O
TEODORO	TEODORO	NNP	B-NP	O
GEOFFREY	GEOFFREY	NNP	I-NP	O
MD	MD	NNP	I-NP	O
DISPOSITION	DISPOSITION	NNP	I-NP	O
:	:	:	O	O
Rehab	Rehab	NNP	B-NP	O
Facility	Facility	NNP	I-NP	O
.	.	.	O	O

CHIEF	CHIEF	NN	B-NP	B-protein
COMPLAINT	COMPLAINT	NN	I-NP	O
:	:	:	O	O
Fever	Fever	NNP	B-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
an	an	DT	B-NP	O
86-year-old	86-year-old	JJ	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diastolic	diastolic	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
,	,	,	O	O
PMR	PMR	NN	B-NP	B-protein
,	,	,	O	O
insulin-dependent	insulin-dependent	JJ	B-NP	O
diabetes	diabete	NNS	I-NP	O
,	,	,	O	O
adrenal	adrenal	JJ	B-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
partial	partial	JJ	B-NP	O
SBO	SBO	NN	I-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
is	be	VBZ	B-VP	O
transferred	transfer	VBN	I-VP	O
from	from	IN	B-PP	O
Shan	Shan	NNP	B-NP	O
Hospitals	Hospitals	NNP	I-NP	O
Of	Of	IN	B-ADJP	O
with	with	IN	B-PP	O
recurrence	recurrence	NN	B-NP	O
of	of	IN	B-PP	O
fever	fever	NN	B-NP	O
after	after	IN	B-PP	O
a	a	DT	B-NP	O
recent	recent	JJ	I-NP	O
discharge	discharge	NN	I-NP	O
from	from	IN	B-PP	O
Ouh	Ouh	NNP	B-NP	O
On	On	NNP	I-NP	O
Valley	Valley	NNP	I-NP	O
Health	Health	NNP	I-NP	O
during	during	IN	B-PP	O
,	,	,	O	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
for	for	IN	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
recent	recent	JJ	I-NP	O
admission	admission	NN	I-NP	O
to	to	TO	B-PP	O
Harbanburkehead	Harbanburkehead	NNP	B-NP	O
Health	Health	NNP	I-NP	O
from	from	IN	B-PP	O
3/25/06	3/25/06	CD	B-NP	O
to	to	TO	B-PP	O
4/3/06	4/3/06	CD	B-NP	O
,	,	,	O	O
during	during	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
urinary	urinary	JJ	I-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
and	and	CC	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
and	and	CC	O	O
discharged	discharge	VBN	B-VP	O
to	to	TO	B-PP	O
Crit	Crit	NNP	B-NP	O
Community	Community	NNP	I-NP	O
Memorial	Memorial	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
PICC	PICC	NN	I-NP	B-cell_line
line	line	NN	I-NP	I-cell_line
for	for	IN	B-PP	O
complete	complete	JJ	B-NP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
and	and	CC	I-NP	O
vancomycin	vancomycin	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
transient	transient	JJ	B-NP	O
hypertension	hypertension	NN	I-NP	O
during	during	IN	B-PP	O
that	that	DT	B-NP	O
previous	previous	JJ	I-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
otherwise	otherwise	RB	B-VP	O
did	do	VBD	I-VP	O
well	well	RB	B-ADVP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
ceftriaxone	ceftriaxone	NN	B-NP	O
,	,	,	O	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	B-NP	O
then	then	RB	I-NP	O
levofloxacin	levofloxacin	NN	B-NP	O
and	and	CC	I-NP	O
vancomycin	vancomycin	NN	I-NP	O
and	and	CC	O	O
discharged	discharge	VBN	B-VP	O
to	to	TO	I-VP	O
rehab	rehab	VB	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
feeling	feel	VBG	I-VP	O
well	well	RB	B-ADVP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
since	since	IN	B-PP	O
then	then	RB	B-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
night	night	NN	I-NP	O
prior	prior	JJ	I-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
temperature	temperature	NN	I-NP	O
of	of	IN	B-PP	O
101.8	101.8	CD	B-NP	O
with	with	IN	B-PP	O
mild	mild	JJ	B-NP	O
nausea	nausea	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
denied	deny	VBD	B-VP	O
any	any	DT	B-NP	O
other	other	JJ	I-NP	O
associated	associated	JJ	I-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
also	also	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
increasing	increase	VBG	I-NP	O
oxygen	oxygen	NN	I-NP	O
requirement	requirement	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
Rehab	Rehab	NNP	I-NP	O
Facility	Facility	NN	I-NP	O
increased	increase	VBD	B-VP	O
from	from	IN	B-PP	O
baseline	baseline	NN	B-NP	O
of	of	IN	B-PP	O
good	good	JJ	B-NP	O
saturations	saturation	NNS	I-NP	O
of	of	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
up	up	IN	B-PP	O
to	to	TO	B-PP	O
requirement	requirement	NN	B-NP	O
of	of	IN	B-PP	O
3	3	CD	B-NP	O
L	L	NN	I-NP	O
nasal	nasal	JJ	I-NP	O
cannula	cannula	NN	I-NP	O
to	to	TO	B-VP	O
maintain	maintain	VB	I-VP	O
her	her	PRP$	B-NP	O
oxygen	oxygen	NN	I-NP	O
saturation	saturation	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Congestive	Congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
in	in	IN	B-PP	O
September	September	NNP	B-NP	O
of	of	IN	B-PP	O
2005	2005	CD	B-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
60	60	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
diastolic	diastolic	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-NP	O
artery	artery	NN	I-NP	O
systolic	systolic	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
of	of	IN	B-PP	O
49	49	CD	B-NP	O
plus	plus	CC	O	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
atrial	atrial	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
and	and	CC	I-NP	O
trace	trace	NN	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
in	in	IN	B-PP	O
all	all	DT	B-NP	O
valves	valve	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

PMR	PMR	NN	B-NP	B-protein
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

GERD	GERD	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Hypothyroidism	Hypothyroidism	NN	B-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

History	History	NN	B-NP	O
of	of	IN	B-PP	O
TIA	TIA	NN	B-NP	B-protein
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Osteoarthritis	Osteoarthritis	NN	B-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Legally	Legally	RB	B-ADJP	O
blind	blind	JJ	I-ADJP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Status	Status	NNP	B-NP	O
post	post	NN	I-NP	O
cholecystectomy	cholecystectomy	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Depression	Depression	NN	B-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

History	History	NN	B-NP	O
of	of	IN	B-PP	O
Nissen	Nissen	NNP	B-NP	O
fundoplication	fundoplication	NN	I-NP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Adrenal	Adrenal	JJ	B-NP	O
insufficiency	insufficiency	NN	I-NP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
steroid	steroid	NN	I-NP	O
use	use	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
,	,	,	O	O
now	now	RB	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
hydrocortisone	hydrocortisone	NN	B-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	VBP	B-VP	O
TRANSFER	TRANSFER	NN	B-NP	O
FROM	FROM	NN	I-NP	O
GOOCHARLE	GOOCHARLE	NN	I-NP	O
HOSPITAL	HOSPITAL	NN	I-NP	O
ARE	ARE	NN	I-NP	O
AS	AS	NN	I-NP	O
FOLLOWS	FOLLOWS	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Levofloxacin	Levofloxacin	NN	B-NP	B-protein
500	500	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
q.	q.	NN	I-NP	I-protein
48	48	CD	I-NP	I-protein
h.	h.	NN	I-NP	I-protein
2	2	CD	I-NP	I-protein
.	.	.	O	O

Vancomycin	Vancomycin	NN	B-NP	B-protein
1	1	CD	I-NP	I-protein
gm	gm	NN	I-NP	I-protein
IV	IV	CD	B-NP	I-protein
q.	q.	NN	I-NP	I-protein
24	24	CD	B-NP	I-protein
h.	h.	NN	I-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

Norvasc	Norvasc	RB	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Lumigan	Lumigan	NNP	B-NP	O
drops	drop	VBZ	B-VP	O
OU	OU	NNP	B-NP	O
nightly	nightly	RB	B-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Dulcolax	Dulcolax	IN	B-PP	O
5	5	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Captopril	Captopril	NNP	B-NP	O
12.5	12.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
8	8	CD	I-NP	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
9	9	CD	I-NP	O
.	.	.	O	O

Insulin	Insulin	NN	B-NP	O
NPH	NPH	NN	I-NP	O
16	16	CD	B-NP	O
units	unit	NNS	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
and	and	CC	I-NP	O
6	6	CD	I-NP	O
units	unit	NNS	I-NP	O
q.p.m.	q.p.m.	NN	B-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

Remeron	Remeron	NNP	B-NP	O
15	15	CD	I-NP	O
mg	mg	NN	I-NP	O
nightly	nightly	RB	B-ADVP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Synthroid	Synthroid	JJ	B-NP	O
88	88	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Multivitamin	Multivitamin	NN	B-NP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Zocor	Zocor	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Iron	Iron	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

Guiatuss	Guiatuss	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
17	17	CD	I-NP	O
.	.	.	O	O

Allegra	Allegra	DT	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Hydrocortisone	Hydrocortisone	NN	B-NP	O
30	30	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
19	19	CD	I-NP	O
.	.	.	O	O

Milk	Milk	NN	B-NP	O
of	of	IN	B-PP	O
magnesia	magnesia	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
20	20	CD	I-NP	O
.	.	.	O	O

Epoetin	Epoetin	NN	B-NP	B-protein
60	60	CD	I-NP	I-protein
,	,	,	I-NP	O
000	000	CD	I-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
every	every	DT	B-NP	O
Saturday	Saturday	NNP	I-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
Sulfa	Sulfa	NN	B-NP	O
,	,	,	O	O
azathioprine	azathioprine	NN	B-NP	O
,	,	,	O	O
sertraline	sertraline	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
metoclopramide	metoclopramide	NN	B-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
never	never	RB	B-ADVP	O
smoked	smoke	VBD	B-VP	O
,	,	,	O	O
use	use	NN	B-NP	O
alcohol	alcohol	NN	I-NP	O
or	or	CC	O	O
drugs	drug	NNS	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
son	son	NN	I-NP	O
is	be	VBZ	B-VP	O
very	very	RB	B-ADJP	O
involved	involve	VBN	I-ADJP	O
and	and	CC	O	O
confirms	confirm	VBZ	B-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
DNR/DNI	DNR/DNI	NNP	B-NP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Noncontributory	Noncontributory	JJ	B-ADJP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	JJ	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
:	:	:	O	O
On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
temperature	temperature	NN	I-NP	O
is	be	VBZ	B-VP	O
98.6	98.6	CD	B-NP	O
,	,	,	O	O
heart	heart	NN	B-NP	O
rate	rate	NN	I-NP	O
70	70	CD	I-NP	O
,	,	,	I-NP	O
respiratory	respiratory	JJ	I-NP	O
rate	rate	NN	I-NP	O
16	16	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
133/61	133/61	CD	I-NP	O
,	,	,	O	O
oxygen	oxygen	NN	B-NP	O
saturation	saturation	NN	I-NP	O
was	be	VBD	B-VP	O
79	79	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
and	and	CC	O	O
increased	increase	VBD	B-VP	O
in	in	IN	B-PP	O
94	94	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
3	3	CD	B-NP	O
L	L	NN	I-NP	O
nasal	nasal	JJ	I-NP	O
cannula	cannula	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
general	general	JJ	B-ADJP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
appeared	appear	VBD	B-VP	O
comfortable	comfortable	JJ	B-ADJP	O
with	with	IN	B-PP	O
pleasant	pleasant	NN	B-NP	O
and	and	CC	I-NP	O
convulsant	convulsant	NN	I-NP	O
and	and	CC	I-NP	O
blind	blind	NN	I-NP	O
.	.	.	O	O

Neck	Neck	NN	B-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
JVP	JVP	NN	I-NP	B-protein
of	of	IN	B-PP	O
7	7	CD	B-NP	O
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
with	with	IN	B-PP	O
left	left	JJ	B-NP	O
basilar	basilar	JJ	I-NP	O
crackles	crackle	NNS	I-NP	O
no	no	DT	B-NP	O
wheezes	wheeze	NNS	I-NP	O
.	.	.	O	O

Heart	Heart	NNP	B-NP	O
was	be	VBD	B-VP	O
regular	regular	JJ	B-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
2/6	2/6	CD	I-NP	O
systolic	systolic	JJ	I-NP	O
ejection	ejection	NN	I-NP	O
murmur	murmur	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
upper	upper	JJ	I-NP	O
sternal	sternal	JJ	I-NP	O
border	border	NN	I-NP	O
.	.	.	O	O

Abdomen	Abdoman	NNS	B-NP	O
was	be	VBD	B-VP	O
soft	soft	JJ	B-ADJP	O
,	,	,	O	O
nontender	nontender	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
nondistended	nondistended	JJ	B-ADJP	O
with	with	IN	B-PP	O
normal	normal	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
.	.	.	O	O

Extremities	Extremity	NNS	B-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
clubbing	clubbing	NN	I-NP	O
,	,	,	O	O
cyanosis	cyanosis	NN	B-NP	O
,	,	,	O	O
or	or	CC	O	O
edema	edema	NN	B-NP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
DATA	DATA	NN	I-NP	O
:	:	:	O	O
On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
were	be	VBD	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
potassium	potassium	NN	B-NP	O
of	of	IN	B-PP	O
4.5	4.5	CD	B-NP	O
,	,	,	O	O
BUN	BUN	NN	B-NP	O
of	of	IN	B-PP	O
23	23	CD	B-NP	O
,	,	,	O	O
creatinine	creatinine	NN	B-NP	B-protein
1.6	1.6	CD	I-NP	I-protein
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
at	at	IN	B-PP	O
her	her	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
of	of	IN	B-PP	O
1.4	1.4	CD	B-NP	O
to	to	TO	B-PP	O
1.6	1.6	CD	B-NP	O
.	.	.	O	O

White	White	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
5.7	5.7	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
27.3	27.3	CD	I-NP	I-protein
from	from	IN	B-PP	O
a	a	DT	B-NP	O
baseline	baseline	NN	I-NP	O
of	of	IN	B-PP	O
26	26	CD	B-NP	O
to	to	TO	B-PP	O
29	29	CD	B-NP	O
,	,	,	O	O
platelets	platelet	NNS	B-NP	B-cell_type
of	of	IN	B-PP	O
347	347	CD	B-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
.	.	.	O	O

Coagulation	Coagulation	NN	B-NP	O
studies	study	NNS	I-NP	O
were	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

Liver	Liver	NN	B-NP	O
function	function	NN	I-NP	O
tests	test	NNS	I-NP	O
were	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

Cardiac	Cardiac	JJ	B-NP	B-protein
enzymes	enzyme	NNS	I-NP	I-protein
were	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
change	change	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
lobe	lobe	NN	I-NP	O
infiltrate	infiltrate	NN	I-NP	O
,	,	,	O	O
since	since	IN	B-PP	O
10/20/06	10/20/06	CD	B-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
EKG	EKG	NN	I-NP	O
showed	show	VBD	B-VP	O
Q-wave	Q-wave	JJ	B-NP	O
flattening	flattening	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
no	no	DT	B-NP	O
changes	change	NNS	I-NP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
prior	prior	JJ	I-NP	O
EKGs	EKG	NNS	I-NP	O
.	.	.	O	O

Normal	Normal	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
.	.	.	O	O

IMPRESSION	IMPRESSION	NN	B-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
an	an	DT	B-NP	O
86-year-old	86-year-old	JJ	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
medical	medical	JJ	I-NP	O
problems	problem	NNS	I-NP	O
including	include	VBG	B-PP	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
,	,	,	O	O
diabetes	diabetes	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
adrenal	adrenal	JJ	B-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
recurrent	recurrent	JJ	B-NP	O
fevers	fever	NNS	I-NP	O
through	through	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
and	and	CC	I-NP	O
vancomycin	vancomycin	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
.	.	.	O	O

Initially	Initially	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
source	source	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
repeated	repeated	JJ	I-NP	O
fevers	fever	NNS	I-NP	O
was	be	VBD	B-VP	O
unclear	unclear	JJ	B-ADJP	O
.	.	.	O	O

Multiple	Multiple	JJ	B-NP	B-cell_line
cultures	culture	NNS	I-NP	I-cell_line
were	be	VBD	B-VP	O
sent	send	VBN	I-VP	O
including	include	VBG	B-PP	O
urine	urine	NN	B-NP	B-cell_line
cultures	culture	NNS	I-NP	I-cell_line
,	,	,	O	O
stool	stool	NN	B-NP	O
studies	study	NNS	I-NP	O
,	,	,	O	O
peripheral	peripheral	JJ	B-NP	B-cell_type
blood	blood	NN	I-NP	I-cell_type
cultures	culture	NNS	I-NP	I-cell_type
and	and	CC	O	O
blood	blood	NN	B-NP	B-cell_line
cultures	culture	NNS	I-NP	I-cell_line
from	from	IN	B-PP	O
the	the	DT	B-NP	O
PICC	PICC	NN	I-NP	B-cell_line
sputum	sputum	NN	I-NP	I-cell_line
cultures	culture	NNS	I-NP	I-cell_line
and	and	CC	O	O
induced	induce	VBD	B-VP	O
sputum	sputum	NN	B-NP	O
with	with	IN	B-PP	O
testing	testing	NN	B-NP	O
for	for	IN	B-PP	O
PCP	PCP	NN	B-NP	B-protein
,	,	,	O	O
given	give	VBN	B-PP	O
her	her	PRP$	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
steroid	steroid	NN	I-NP	O
uses	use	NNS	I-NP	O
without	without	IN	B-PP	O
PCP	PCP	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
.	.	.	O	O

All	All	DT	B-NP	O
of	of	IN	B-PP	O
these	these	DT	B-NP	O
came	come	VBD	B-VP	O
back	back	RB	B-ADJP	O
negative	negative	JJ	I-ADJP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
exception	exception	NN	I-NP	O
of	of	IN	B-PP	O
one	one	CD	B-NP	O
blood	blood	NN	I-NP	O
culture	culture	NN	I-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
PICC	PICC	NN	I-NP	B-protein
,	,	,	O	O
which	which	WDT	B-NP	O
grew	grow	VBD	B-VP	O
coagulase	coagulase	NN	B-NP	O
negative	negative	JJ	I-NP	O
Staphylococcus	Staphylococcus	FW	I-NP	O
aureus	aureus	FW	I-NP	O
.	.	.	O	O

So	So	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
PICC	PICC	NN	I-NP	B-cell_line
line	line	NN	I-NP	I-cell_line
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
tip	tip	NN	I-NP	O
sent	send	VBN	B-VP	O
for	for	IN	B-PP	O
culture	culture	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

After	After	IN	B-PP	O
discontinuation	discontinuation	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
PICC	PICC	NN	I-NP	B-cell_line
line	line	NN	I-NP	I-cell_line
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
further	further	JJ	I-NP	O
fevers	fever	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
remainder	remainder	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
72	72	CD	B-NP	O
hours	hour	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
induced	induce	VBN	I-NP	O
sputum	sputum	NN	I-NP	O
for	for	IN	B-PP	O
PCP	PCP	NN	B-NP	B-protein
was	be	VBD	B-VP	O
also	also	RB	B-ADVP	O
negative	negative	JJ	B-ADJP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
then	then	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
PCP	PCP	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
with	with	IN	B-PP	O
Mepron	Mepron	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
given	give	VBN	B-VP	O
her	her	PRP$	B-NP	O
sulfa	sulfa	NN	I-NP	O
allergy	allergy	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
continued	continue	VBN	I-VP	O
until	until	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
completed	complete	VBN	I-VP	O
her	her	PRP$	B-NP	O
gradual	gradual	JJ	I-NP	O
tapper	tapper	NN	I-NP	O
off	off	IN	B-PP	O
of	of	IN	B-PP	O
steroids	steroid	NNS	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
completed	complete	VBD	B-VP	O
the	the	DT	B-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
and	and	CC	I-NP	O
vancomycin	vancomycin	NN	I-NP	O
courses	course	NNS	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
were	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
previous	previous	JJ	I-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
for	for	IN	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
and	and	CC	O	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
further	further	JJ	I-NP	O
fevers	fever	NNS	I-NP	O
after	after	IN	B-PP	O
completing	complete	VBG	B-VP	O
these	these	DT	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
PPD	PPD	NN	I-NP	B-protein
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Endocrine	Endocrine	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
hypothyroidism	hypothyroidism	NN	B-NP	O
,	,	,	O	O
adrenal	adrenal	JJ	B-NP	O
insufficiency	insufficiency	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
chronic	chronic	JJ	B-NP	O
steroids	steroid	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
and	and	CC	I-NP	O
insulin-dependent	insulin-dependent	JJ	I-NP	O
diabetes	diabete	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
TSH	TSH	NN	I-NP	O
was	be	VBD	B-VP	O
checked	check	VBN	I-VP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

So	So	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Synthroid	Synthroid	NNP	B-NP	O
.	.	.	O	O

Further	Further	JJ	B-NP	O
instructions	instruction	NNS	I-NP	O
through	through	IN	B-PP	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
provider	provider	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
hydrocortisone	hydrocortisone	NN	I-NP	O
was	be	VBD	B-VP	O
slightly	slightly	RB	I-VP	O
decreased	decrease	VBN	I-VP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
slow	slow	JJ	I-NP	O
taper	taper	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
further	further	RBR	B-ADJP	O
directed	direct	VBN	I-ADJP	O
by	by	IN	B-PP	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
provider	provider	NN	I-NP	O
after	after	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
insulin	insulin	NN	I-NP	O
regimen	regimen	NN	I-NP	O
was	be	VBD	B-VP	O
up	up	RB	I-VP	O
titrated	titrate	VBN	I-VP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
addition	addition	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
q.a.c.	q.a.c.	NNP	I-NP	O
Novalog	Novalog	NNP	I-NP	O
,	,	,	O	O
given	give	VBN	B-PP	O
her	her	PRP$	B-NP	O
high	high	JJ	I-NP	O
fingerstick	fingerstick	NN	I-NP	O
blood	blood	NN	I-NP	O
glucoses	glucose	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
continue	continue	VB	I-VP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
increased	increase	VBN	I-NP	O
regimen	regimen	NN	I-NP	O
after	after	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
.	.	.	O	O

On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
hypoxic	hypoxic	JJ	B-ADJP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
oxygen	oxygen	NN	I-NP	O
saturation	saturation	NN	I-NP	O
of	of	IN	B-PP	O
79	79	CD	B-NP	O
%	%	NN	I-NP	O
to	to	TO	I-NP	O
80	80	CD	I-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
increased	increase	VBD	B-VP	O
to	to	TO	B-PP	O
93	93	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
2	2	CD	B-NP	O
L	L	NN	I-NP	O
to	to	TO	B-PP	O
3	3	CD	B-NP	O
L	L	NN	I-NP	O
of	of	IN	B-PP	O
nasal	nasal	JJ	B-NP	O
cannula	cannula	NN	I-NP	O
.	.	.	O	O

Given	Give	VBN	B-PP	O
this	this	DT	B-NP	O
new	new	JJ	I-NP	O
hypoxia	hypoxia	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
chronic	chronic	JJ	I-NP	O
decreased	decrease	VBN	I-NP	O
ambulation	ambulation	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
sent	send	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
CT	CT	NN	I-NP	O
angiogram	angiogram	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
chest	chest	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
for	for	IN	B-PP	O
PE	PE	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
study	study	NN	I-NP	O
also	also	RB	B-ADVP	O
shows	show	VBZ	B-VP	O
small	small	JJ	B-NP	O
bilateral	bilateral	JJ	I-NP	O
pleural	pleural	JJ	I-NP	O
effusion	effusion	NN	I-NP	O
and	and	CC	O	O
mild	mild	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

Resolution	Resolution	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
previous	previous	JJ	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
and	and	CC	O	O
possibly	possibly	RB	B-NP	O
reactive	reactive	JJ	I-NP	O
mediastinal	mediastinal	JJ	I-NP	O
lymphadenopathy	lymphadenopathy	NN	I-NP	O
.	.	.	O	O

Given	Give	VBN	B-PP	O
this	this	DT	B-NP	O
data	datum	NNS	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
Lasix	Lasix	NN	B-NP	O
with	with	IN	B-PP	O
diuresis	diuresis	NN	B-NP	O
,	,	,	O	O
titrated	titrate	VBN	B-VP	O
to	to	TO	B-PP	O
1	1	CD	B-NP	O
L	L	NN	I-NP	O
negative	negative	JJ	B-ADJP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
sound	sound	RB	B-ADVP	O
well	well	RB	B-ADVP	O
.	.	.	O	O

Given	Give	VBN	B-PP	O
this	this	DT	B-NP	O
data	datum	NNS	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
diuresis	diuresis	NN	I-NP	O
titrated	titrate	VBD	B-VP	O
to	to	TO	B-PP	O
1	1	CD	B-NP	O
L	L	NN	I-NP	O
negative	negative	JJ	B-ADJP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
and	and	CC	O	O
responded	respond	VBD	B-VP	O
well	well	RB	B-ADVP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
decreasing	decrease	VBG	I-VP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
and	and	CC	O	O
improved	improve	VBN	B-NP	O
room	room	NN	I-NP	O
air	air	NN	I-NP	O
oxygen	oxygen	NN	I-NP	O
saturation	saturation	NN	I-NP	O
up	up	IN	B-NP	O
to	to	TO	I-NP	O
85	85	CD	I-NP	O
%	%	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
continued	continue	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
oxygen	oxygen	NN	B-NP	O
of	of	IN	B-PP	O
2	2	CD	B-NP	O
L	L	NN	I-NP	O
nasal	nasal	JJ	I-NP	O
cannula	cannula	NN	I-NP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
oxygen	oxygen	NN	I-NP	O
saturation	saturation	NN	I-NP	O
and	and	CC	O	O
is	be	VBZ	B-VP	O
anticipated	anticipate	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
successful	successful	JJ	I-NP	O
gradual	gradual	JJ	I-NP	O
wean	wean	NN	I-NP	O
from	from	IN	B-PP	O
oxygen	oxygen	NN	B-NP	O
as	as	IN	B-PP	O
her	her	PRP$	B-NP	O
diuresis	diuresis	NN	I-NP	O
continue	continue	VBP	B-VP	O
after	after	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
Pulmonary	Pulmonary	NNP	I-NP	O
Service	Service	NNP	I-NP	O
was	be	VBD	B-VP	O
consulted	consult	VBN	I-VP	O
and	and	CC	O	O
followed	follow	VBD	B-VP	O
her	her	PRP	B-NP	O
agreeing	agree	VBG	B-VP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
diagnosis	diagnosis	NN	I-NP	O
of	of	IN	B-PP	O
pulmonary	pulmonary	JJ	B-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

They	They	PRP	B-NP	O
also	also	RB	B-ADVP	O
recommended	recommend	VBD	B-VP	O
a	a	DT	B-NP	O
followup	followup	NN	I-NP	O
noncontrast	noncontrast	NN	I-NP	O
chest	chest	NN	I-NP	O
CT	CT	NN	I-NP	O
in	in	IN	B-PP	O
2	2	CD	B-NP	O
to	to	TO	I-NP	O
4	4	CD	I-NP	O
weeks	week	NNS	I-NP	O
after	after	IN	B-SBAR	O
discharge	discharge	NN	B-NP	O
to	to	TO	B-VP	O
reevaluate	reevaluate	VB	I-VP	O
her	her	PRP$	B-NP	O
mediastinal	mediastinal	JJ	I-NP	O
lymphadenopathy	lymphadenopathy	NN	I-NP	O
after	after	IN	B-PP	O
a	a	DT	B-NP	O
period	period	NN	I-NP	O
of	of	IN	B-PP	O
diuresis	diuresis	NN	B-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
followup	followup	NN	I-NP	O
appointment	appointment	NN	I-NP	O
was	be	VBD	B-VP	O
made	make	VBN	I-VP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Soucek	Soucek	NNP	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
Chest	Chest	NNP	I-NP	O
Clinic	Clinic	NNP	I-NP	O
at	at	IN	B-PP	O
Sio	Sio	NNP	B-NP	O
Sane	Sane	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
for	for	IN	B-PP	O
two	two	CD	B-NP	O
weeks	week	NNS	I-NP	O
following	follow	VBG	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-NP	O
function	function	NN	I-NP	O
test	test	NN	I-NP	O
were	be	VBD	B-VP	O
completed	complete	VBN	I-VP	O
,	,	,	O	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
restrictive	restrictive	JJ	I-NP	O
defect	defect	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
the	the	DT	B-NP	O
Pulmonary	Pulmonary	NNP	I-NP	O
Service	Service	NNP	I-NP	O
felt	feel	VBD	B-VP	O
could	could	MD	B-VP	O
be	be	VB	I-VP	O
attributed	attribute	VBN	I-VP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
volume	volume	NN	I-NP	O
overload	overload	NN	I-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
echo	echo	NN	I-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
increased	increase	VBN	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
artery	artery	NN	I-NP	O
systolic	systolic	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
at	at	IN	B-PP	O
47	47	CD	B-NP	O
plus	plus	CC	O	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
atrial	atrial	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
previous	previous	JJ	B-NP	O
echo	echo	NN	I-NP	O
done	do	VBN	B-VP	O
in	in	IN	B-PP	O
September	September	NNP	B-NP	O
of	of	IN	B-PP	O
2005	2005	CD	B-NP	O
.	.	.	O	O

Thus	Thus	RB	B-ADVP	O
,	,	,	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
considered	consider	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
new	new	JJ	B-NP	O
pathology	pathology	NN	I-NP	O
,	,	,	O	O
nor	nor	CC	O	O
likely	likely	RB	B-ADJP	O
related	relate	VBN	I-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
new	new	JJ	I-NP	O
hypoxia	hypoxia	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Hematologic	Hematologic	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
known	known	JJ	I-NP	O
diagnosis	diagnosis	NN	I-NP	O
of	of	IN	B-PP	O
iron	iron	NN	B-NP	O
deficiency	deficiency	NN	I-NP	O
anemia	anemia	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
anemia	anemia	NN	B-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
is	be	VBZ	B-VP	O
maintaining	maintain	VBG	I-VP	O
on	on	IN	B-PP	O
iron	iron	NN	B-NP	O
and	and	CC	I-NP	O
epoetin	epoetin	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
were	be	VBD	B-VP	O
no	no	DT	B-NP	O
signs	sign	NNS	I-NP	O
or	or	CC	I-NP	O
symptoms	symptom	NNS	I-NP	O
of	of	IN	B-PP	O
bleeding	bleed	VBG	B-VP	O
throughout	throughout	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
not	not	RB	O	O
required	require	VBD	B-VP	O
a	a	DT	B-NP	O
blood	blood	NN	I-NP	O
transfusion	transfusion	NN	I-NP	O
at	at	IN	B-PP	O
any	any	DT	B-NP	O
point	point	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
continue	continue	VB	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
outpatient	outpatient	NN	I-NP	O
regimen	regimen	NN	I-NP	O
of	of	IN	B-PP	O
iron	iron	NN	B-NP	O
and	and	CC	I-NP	O
epoetin	epoetin	NN	I-NP	O
after	after	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

Iron	Iron	NN	B-NP	O
studies	study	NNS	I-NP	O
done	do	VBN	B-VP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
showed	show	VBD	B-VP	O
adequate	adequate	JJ	B-NP	O
iron	iron	NN	I-NP	O
repletion	repletion	NN	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
current	current	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
ischemia	ischemia	NN	B-NP	O
throughout	throughout	IN	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

Given	Give	VBN	B-PP	O
her	her	PRP$	B-NP	O
findings	finding	NNS	I-NP	O
of	of	IN	B-PP	O
pulmonary	pulmonary	JJ	B-NP	O
edema	edema	NN	I-NP	O
on	on	IN	B-PP	O
chest	chest	NN	B-NP	O
CT	CT	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diastolic	diastolic	JJ	B-NP	O
congestive	congestive	JJ	I-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Lasix	Lasix	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
with	with	IN	B-PP	O
effective	effective	JJ	B-NP	O
diuresis	diuresis	NN	I-NP	O
noted	note	VBD	B-VP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
transitioned	transitione	VBN	I-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
p.o.	p.o.	NN	I-NP	O
regimen	regimen	NN	I-NP	O
of	of	IN	B-PP	O
40	40	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
continued	continue	VBN	I-VP	O
after	after	IN	B-PP	O
discharge	discharge	NN	B-NP	O
and	and	CC	O	O
titrated	titrate	VBN	B-VP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
weight	weight	NN	I-NP	O
loss	loss	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
outpatient	outpatient	NN	I-NP	O
Zocor	Zocor	NNP	I-NP	O
,	,	,	O	O
Norvasc	Norvasc	NNP	B-NP	O
and	and	CC	O	O
lisinopril	lisinopril	NN	B-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
received	receive	VBD	B-VP	O
Mucomyst	Mucomyst	NN	B-NP	O
and	and	CC	I-NP	O
bicarbonate	bicarbonate	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
IV	IV	CD	I-NP	O
fluids	fluid	NNS	I-NP	O
,	,	,	O	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
CT	CT	NN	I-NP	O
angiogram	angiogram	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
chest	chest	NN	I-NP	O
with	with	IN	B-PP	O
prophylaxis	prophylaxis	NN	B-NP	O
against	against	IN	B-PP	O
contrast	contrast	NN	B-NP	O
nephropathy	nephropathy	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
at	at	IN	B-PP	O
1.6	1.6	CD	B-NP	O
for	for	IN	B-PP	O
remainder	remainder	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
72	72	CD	B-NP	O
hours	hour	NNS	I-NP	O
.	.	.	O	O

All	All	DT	B-NP	O
mediations	mediation	NNS	I-NP	O
were	be	VBD	B-VP	O
appropriately	appropriately	RB	I-VP	O
renally	renally	RB	I-VP	O
dosed	dose	VBN	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
continue	continue	VB	I-VP	O
followup	followup	NN	B-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
provider	provider	NN	I-NP	O
regarding	regard	VBG	B-VP	O
her	her	PRP$	B-NP	O
chronic	chronic	JJ	I-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
future	future	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Fluid	Fluid	NN	B-NP	O
,	,	,	O	O
Electrolytes	Electrolyte	NNS	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Nutrition	Nutrition	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
any	any	DT	B-NP	O
IV	IV	CD	I-NP	O
fluids	fluid	NNS	I-NP	O
except	except	IN	B-PP	O
as	as	IN	B-PP	O
prophylaxis	prophylaxis	NN	B-NP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
CT	CT	NN	I-NP	O
angiogram	angiogram	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
potassium	potassium	NN	I-NP	O
and	and	CC	I-NP	O
magnesium	magnesium	NN	I-NP	O
were	be	VBD	B-VP	O
repeated	repeat	VBN	I-VP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
renal	renal	JJ	I-NP	O
,	,	,	I-NP	O
cardiac	cardiac	JJ	I-NP	O
ADA	ADA	NN	I-NP	O
diet	diet	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Prophylaxis	Prophylaxis	NN	B-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
t.i.d.	t.i.d.	NN	B-NP	O
subq	subq	NN	I-NP	O
heparin	heparin	NN	I-NP	O
for	for	IN	B-PP	O
DVT	DVT	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
and	and	CC	I-NP	O
Nexium	Nexium	NN	I-NP	O
for	for	IN	B-PP	O
GI	GI	NN	B-NP	B-protein
prophylaxis	prophylaxis	NN	I-NP	I-protein
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
an	an	DT	B-NP	O
aggressive	aggressive	JJ	I-NP	O
bowel	bowel	NN	I-NP	O
regimen	regimen	NN	I-NP	O
,	,	,	O	O
given	give	VBN	B-PP	O
her	her	PRP$	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
constipation	constipation	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Code	Code	NNP	B-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
DNR/DNI	DNR/DNI	NN	B-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
son	son	NN	I-NP	O
John	John	NNP	I-NP	O
Durazo	Durazo	NNP	I-NP	O
,	,	,	O	O
is	be	VBZ	B-VP	O
the	the	DT	B-NP	O
healthcare	healthcare	NN	I-NP	O
proxy	proxy	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
PLAN	PLAN	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
Mclemens	Mclemens	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
Of	Of	NNP	I-NP	O
County	County	NNP	I-NP	O
to	to	TO	B-VP	O
continue	continue	VB	I-VP	O
physical	physical	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
to	to	TO	B-VP	O
regain	regain	VB	I-VP	O
some	some	DT	B-NP	O
independence	independence	NN	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
activities	activity	NNS	I-NP	O
of	of	IN	B-PP	O
daily	daily	JJ	B-NP	O
living	living	NN	I-NP	O
and	and	CC	O	O
more	more	RBR	B-ADVP	O
specifically	specifically	RB	I-ADVP	O
to	to	TO	B-VP	O
regain	regain	VB	I-VP	O
some	some	DT	B-NP	O
independence	independence	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
activities	activity	NNS	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
enjoys	enjoy	VBZ	B-VP	O
such	such	JJ	B-PP	O
as	as	IN	I-PP	O
playing	play	VBG	B-VP	O
the	the	DT	B-NP	O
piano	piano	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
have	have	VB	I-VP	O
followup	followup	NN	B-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
provider	provider	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Pacetti	Pacetti	NNP	I-NP	O
regarding	regard	VBG	B-VP	O
general	general	JJ	B-NP	O
plan	plan	NN	I-NP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
care	care	NN	I-NP	O
including	include	VBG	B-PP	O
gradual	gradual	JJ	B-NP	O
hydrocortisone	hydrocortisone	NN	I-NP	O
taper	taper	NN	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
Lasix	Lasix	NNP	I-NP	O
dosing	dosing	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
diabetes	diabetes	NN	I-NP	O
management	management	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
also	also	RB	I-VP	O
followup	followup	VB	I-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
chest	chest	NN	I-NP	O
clinic	clinic	NN	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Tobola	Tobola	NNP	I-NP	O
regarding	regard	VBG	B-VP	O
her	her	PRP$	B-NP	O
PCP	PCP	NN	I-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
possibly	possibly	RB	I-NP	O
of	of	IN	B-PP	O
repeat	repeat	NN	B-NP	O
chest	chest	NN	I-NP	O
CT	CT	NN	I-NP	O
regarding	regard	VBG	B-VP	O
the	the	DT	B-NP	O
question	question	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
mediastinal	mediastinal	JJ	I-NP	O
lymphadenopathy	lymphadenopathy	NN	I-NP	O
seen	see	VBN	B-VP	O
on	on	IN	B-PP	O
CT	CT	NN	B-NP	B-protein
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Albuterol	Albuterol	NN	B-NP	O
nebulizer	nebulizer	NN	I-NP	O
q.	q.	NN	I-NP	O
4	4	CD	I-NP	O
h.	h.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
wheezing	wheezing	NN	I-NP	O
or	or	CC	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Norvasc	Norvasc	RB	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Mepron	Mepron	NN	B-NP	B-protein
750	750	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
5	5	CD	I-NP	I-protein
.	.	.	O	O

Lumigan	Lumigan	NNP	B-NP	O
one	one	CD	I-NP	O
drop	drop	NN	I-NP	O
OU	OU	NN	I-NP	O
nightly	nightly	RB	B-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Dulcolax	Dulcolax	IN	B-PP	O
5	5	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
8	8	CD	I-NP	O
.	.	.	O	O

Nexium	Nexium	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Iron	Iron	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

Allegra	Allegra	DT	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
12	12	CD	I-NP	O
.	.	.	O	O

Neurontin	Neurontin	NN	B-NP	O
300	300	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
nightly	nightly	RB	I-ADVP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Hydrocortisone	Hydrocortisone	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
14	14	CD	I-NP	O
.	.	.	O	O

Aspart	Aspart	NN	B-NP	O
insulin	insulin	NN	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
q.a.c.	q.a.c.	NN	I-NP	O
15	15	CD	I-NP	O
.	.	.	O	O

Aspart	Aspart	NN	B-NP	O
insulin	insulin	NN	I-NP	O
8	8	CD	B-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
q.a.c.	q.a.c.	NN	I-NP	O
16	16	CD	I-NP	O
.	.	.	O	O

NPH	NPH	NN	B-NP	O
insulin	insulin	NN	I-NP	O
20	20	CD	B-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
and	and	CC	I-NP	O
6	6	CD	I-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
nightly	nightly	RB	B-ADVP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Synthroid	Synthroid	JJ	B-NP	O
88	88	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Lisinopril	Lisinopril	NNP	B-NP	O
7.5	7.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

19	19	CD	B-NP	O
.	.	.	O	O

Remeron	Remeron	NNP	B-NP	O
15	15	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
nightly	nightly	RB	I-ADVP	O
.	.	.	O	O

20	20	CD	B-NP	O
.	.	.	O	O

Senna	Senna	NNP	B-NP	O
2	2	CD	I-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
21	21	CD	I-NP	O
.	.	.	O	O

Zocor	Zocor	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
nightly	nightly	RB	I-ADVP	O
.	.	.	O	O

22	22	CD	B-NP	O
.	.	.	O	O

Multivitamin	Multivitamin	NN	B-NP	O
one	one	CD	I-NP	O
tablet	tablet	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

23	23	CD	B-NP	O
.	.	.	O	O

Epoetin	Epoetin	NN	B-NP	B-protein
60	60	CD	I-NP	I-protein
,	,	,	I-NP	O
000	000	CD	I-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
every	every	DT	B-NP	O
Saturday	Saturday	NNP	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
7-5594516	7-5594516	CD	B-NP	O
CSSten	CSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
PODRASKY	PODRASKY	NNP	B-NP	O
,	,	,	O	O
KEVEN	KEVEN	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
ESKE	ESKE	NNP	B-NP	O
,	,	,	O	O
MAURICIO	MAURICIO	NNP	B-NP	O
THAD	THAD	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
3139468	3139468	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
1/5/06	1/5/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
1/5/06	1/5/06	CD	B-NP	O

